GSK1360707F

GSK1360707F is a chemical compound developed by GlaxoSmithKline, a British multinational pharmaceutical company. It is a potent and selective inhibitor of the Fluoride Resistance Determinant F (FrdF) enzyme, which is part of the FrdABC complex involved in bacterial resistance to fluoride.

History[edit | edit source]

GSK1360707F was first synthesized by GlaxoSmithKline as part of their research into novel antibacterial agents. The compound was identified as a potent inhibitor of the FrdF enzyme, which is a key component of the FrdABC complex that confers resistance to fluoride in many bacterial species.

Mechanism of Action[edit | edit source]

GSK1360707F acts by binding to the FrdF enzyme and inhibiting its activity. This prevents the FrdABC complex from functioning properly, which in turn makes the bacteria susceptible to the toxic effects of fluoride. The exact binding site and mode of action of GSK1360707F are still under investigation.

Potential Applications[edit | edit source]

Due to its ability to inhibit the FrdF enzyme, GSK1360707F has potential applications in the treatment of bacterial infections, particularly those caused by fluoride-resistant strains. However, further research is needed to determine the compound's efficacy and safety in clinical settings.

References[edit | edit source]

This chemistry-related article is a stub. You can help WikiMD by expanding it.

This pharmacology-related article is a stub. You can help WikiMD by expanding it.

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.